New blood thinner could make heart bypass safer during surgery

NCT ID NCT07514962

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether giving the blood thinner cangrelor through a vein during minimally invasive heart bypass surgery is safe and practical. The goal is to prevent dangerous blood clots while the patient is on the operating table. Researchers will compare 30 patients receiving cangrelor during surgery to similar patients from the past who received standard care with aspirin. The main focus is on whether cangrelor increases the risk of serious bleeding.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
cangrelor (a fast-acting blood thinner given through a vein)
What this could lead to
If successful, this could make minimally invasive heart bypass surgery safer by preventing blood clots during the procedure without increasing bleeding complications.
What could go wrong
This is a small, early-phase study with only 30 participants, so results may not apply to all patients. There is still a risk of bleeding or other complications despite careful monitoring.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTIPLATELET THERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Istituto Cardiocentro Ticino

    RECRUITING

    Lugano, Ch/ti, 6900, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.